Travis Mickle
North Liberty, IA (USA)
Role(s):
C-Level Executive (CEO, CFO, etc.)
KemPharm, Inc.
Find More Startups
Startup
Location:
North Liberty
Industry:
Pharmaceuticals
Year Founded:
2006
Number Employees:
10-50 people
Business Stage:
Growth (not profitable)
Entity Type:
"C" Corporation
Description:
KemPharm is a development stage biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach. The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases. KemPharm’s lead clinical candidate, KP201, is in development for the treatment of acute moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the second quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm’s pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD. For more information on KemPharm, please visit the company’s website at (URL removed)